Background: Randomized controlled trials (RCTs) are considered the gold standard for assessing efficacy and short-term harm of medicines. However, several studies have come to the conclusion that harm is less well reported than efficacy outcomes.
INTRODUCTION
As a basis of deontology in medicine, pharmacologic and nonpharmacologic interventions are assessed through a complex process, including randomized controlled trials (RCTs). 1, 2 They are considered the gold standard to prospectively and accurately assess harm and efficacy of a therapeutic intervention, [3] [4] [5] and they often report data on medications that are said to be both safe and effective.
However, when looking carefully at the data, the effectiveness is often well studied and documented, whereas the safety is less well so. Several studies have come to the conclusion that benefits are much more likely to be reported in RCTs than safety and harm. [6] [7] [8] [9] This is unfortunate since the safety of a medication is almost as important as its efficacy when a therapeutic choice has to be made in daily care. Moreover, the way of reporting harm results in RCTs have also been criticised because of possible misinterpretation, 10 and the quality of the report is also likely to be related to external factors (eg, study design). 11 In this context, several initiatives emerged, 12, 13 including the CONSORT (consolidated standards of reporting trials) statement, 14, 15 essentially focusing on the harmonization of RCT reports, followed by its extension to harm reports in 2004. 3 The main objective of the present study was to describe harm reports in dermatologic RCTs, particularly focusing on the adequate reporting of harm and its severity. The secondary objective was to assess parameters that could influence the quality of harm reporting.
METHODS
A methodologic systematic review of manuscripts on dermatologic RCTs was conducted. 
Checklist elaboration
A checklist was constructed before selection of the articles to be included in the study and used as a basis for data extraction. Our checklist was based on that developed by the CONSORT 2004 group, 3 including items found to be critical in similar studies 11, 16, 17 and possible predictors that might influence harm reporting.
Identification of articles to include
Every issue published from January 1, 2010, to December 31, 2014, was manually listed from the journals' websites. Supplements focusing on annals of congresses were excluded. One third of all the published issues were randomly selected. All selected issues were manually screened to extract all articles fulfilling our inclusion criteria. For cases in which the selected article was in fact an ancillary report not reporting harm, we searched and analysed the primary study.
Data collection
Two investigators (CH and OBS) analysed each selected article, independently from the other. Disagreements were discussed and when necessary, a third investigator (LF) was involved. Before conducting the present study, a feasibility study was carried out on 7 dermatologic RCTs published before 2010.
Outcomes of interest and definitions Adequate report of harm and severity of harm. We agreed that an adequate report of harm and severity of harm had to use numerical data on adverse events for both the experimental and control groups rather than a general statement on fewer adverse events in the text, tables, or figures. If authors specified in the article that no adverse events or no serious or nonserious adverse event occurred during the trial, we agreed this could be an adequate report of harm or severity of harm only in cases in which the authors had well defined methods for collecting harm and severity of harm in the material and methods section.
Perfect report and discussion of harm. We defined a perfect report as a report that included (1) a description of safety issues in the abstract, (2) safety specifications in introduction, (3) numeric data on adverse events for both experimental and control groups, (4) numeric data on the severity of adverse events for both experimental and control groups, and (5) discussion of the harm in the discussion section. A description of safety issues was not required for research letters.
Explanatory variables
Seventeen items were listed in the checklist and considered as possible predictors of the 3 outcomes of interest (Supplemental Table I , available at http: www.jaad.org).
Statistical analyses
All data analyses were performed using SAS for academics software (SAS Institute, Inc, Cary, North Carolina, USA). The proportions of articles adequately reporting harm, reporting severity of harm, and discussing harm were first described. Secondly, possible associations between explanatory variables and each outcome of interest were analyzed using the Student t test or unpaired
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Harm is less well reported than efficacy outcomes in randomized controlled trials. In dermatology journals, harm is quite well reported. Efforts should be made on reporting severity of harm. Wilcoxon-Mann-Whitney test for quantitative variables and the chi-square test or Fisher's exact test for qualitative variables. Finally, explanatory variables associated with 1 of the outcomes of interest with a P value #.2 in univariate analyses were included in a multivariate logistic regression model, using the backward elimination variable selection procedure. Pertinent interaction terms were included in the models, but no association was found. These terms were therefore excluded from the models.
RESULTS
A total of 126 articles were selected (Fig 1) . Table I describes the main characteristics of the 110 assessed reports. Most of the trials evaluated noncosmetic (84.5%), pharmacologic (66.4%), or noninnovative (74.5%) experimental interventions. More than 90% of these clinical trials were reported in 3 journals (ie, JAAD, BJD, and JEADV).
Adequate report of harm
Eighty out of 110 publications (72.7%) adequately reported harm, 17 (15.5%) partially reported harm (using numeric data in only 1 group [n = 8] or using only generic statement [n = 9]), and 13 (11.8%) did not report harm at all (Table II) . The explanatory variables associated with the odds of harm being adequately reported are in Table III . In multivariate analysis, harm was more likely to be adequately reported in multicenter trials (OR 4.41, 95% confidence interval [CI] 1.60-12.35 compared with monocentric studies, P = .005), and in trials using a predefined method for collecting data on harm (OR 5.93, 95% CI 2.26-15.56, P = .0003).
Report of severity of harm
Fifty-seven out of 110 publications (51.8%) adequately reported severity of harm, 14 (12.7%) partially reported severity of harm (ie, using numeric data for only 1 group [n = 4] or using only generic statements [n = 10]), and 39 (35.5%) did not report severity at all (Table II) . The predictors associated in univariate analyses with the odds of the severity being adequately reported are shown in Table IV . In multivariate analysis, severity of harm was more adequately reported in RCTs on pharmacologic interventions (OR 6.48, 95% CI 2.00-21.0 when compared with nonpharmacologic treatment, P = .002) and in studies in which a method for collecting harm (OR 5.65, 95% CI 2.00-16.4, P = .002) and harm severity (OR 3.60, 95% CI 1.00-12.8, P = .04) was defined before the start of the study.
Perfect report and discussion of harm
Forty-four out of 110 publications (40%) perfectly reported and discussed harm (Table II) . In multivariate analyses, harm was more likely to be perfectly reported and discussed in multicenter trials (OR 6.00, 95% CI 2.40-15.3 compared with monocentric studies, P = .0002) and in trials in which a predefined method was used to collect harm (OR 8.90, 95% CI 2.80-27.7, P = .0002). A sensitivity analysis was performed after deleting the item safety report in the introduction from the definition of a perfect report. Fifty publications (45.5%) then perfectly reported and discussed harm. No changes in the predictors of reporting were evidenced when rerunning the multivariate analysis.
DISCUSSION
In the present study analysing 110 dermatologic RCTs published in 5 dermatologic journals over the past 5 years, we found that the global safety reporting was relatively good in comparison with other medical fields. On the other hand, an effort should probably be made to better report severity of harm and better discussed it.
In a study published in 2001 that assessed completeness of safety reporting in 7 medical areas, it was found that severity of harm was adequately reported in only 39% of the articles. 11 This statistic was only 18% in a study describing the completeness of safety reporting in articles evaluating complementary and alternative medicine trials published in 2011. 17 On the other hand, the reporting of harm is better in high impact factor medical journals. In a study performed in 2007 regarding reporting of safety in 133 studies published in 6 generally high impact factor medical journals, it was found that adverse events were adequately reported in 84.2% of articles, and severity in 72.9%. 8 In our study, reporting of harm and its severity were much more likely to be adequate in multicenter trials and in trials in which a method for collecting harm and its severity had been predefined.
Multicenter studies probably involve higher requirements concerning the monitoring of study subjects and harm reporting. If adequate methods for collecting data on harm leads to better reporting on safety and harm, efforts to improve data collection need to be decided on during the planning of the study and mainly depends on investigators' willingness to acquire the information and much less on an editorial decision of the publishing journal. If harm is not adequately collected, it cannot be adequately reported. Therefore, these efforts should probably be made upstream to publication.
Adequate reporting of harm severity was also found to be of higher quality in RCTs evaluating pharmacologic treatments. For some, nonpharmacologic trials might be synonymous of cosmetological trials or trials that induce less or no adverse events (in comparison to trials assessing pharmacologic treatments). In many cases, this belief is false. Firstly, cosmetological products have also generated considerable safety issues that led to the initiation of cosmetovigilance. Secondly, nonpharmacologic RCTs also include assessment of interventions indicated in severe and life-threatening diseases, such as radiotherapy.
The limitations of this research must be acknowledged. The present assessment was conducted on RCTs published in 5 dermatologic journals that were arbitrarily chosen. The generalizability of the results might be consequently limited. However, most of the RCTs published in dermatologic journals are published in the 5 journals chosen. Further, this assessment was restricted to RCTs and did not take into account the report of harm in cohorts or observational studies, in which it is more appropriate to report mid-term and long-term safeties. Moreover, a lack of statistical power could also be discussed for explaining the lack of association between some explanatory variables underrepresented in the study population (eg, pediatric trials) and the outcomes of interest.
Conclusion
Harm is quite well reported in dermatologic RCTs, at least in the 5 journals assessed. Efforts should probably focus on better reporting and discussing of severity of harm. Investigators should adequately predefine their methods for collecting data on harm and its severity (eg, using severity grades). This would allow for the accurate, transparent, and ethical reporting of safety to researchers and lecturers, and better relay more complete information on possible safety concerns that need to be proactively monitored. Age of study subjects 7
Supplemental
Sample size 8
Duration of treatment and follow-up 9
Field of interest (cosmetology vs other fields) 10 Treatment being evaluated (ie, pharmacologic vs nonpharmacologic) 11 Type of comparator used in the control group (ie, placebo vs nonplacebo) 12 Old vs innovative y drug as the experimental intervention 13
Type of study (ie, monocentric or multicentric) 14 Blinding process 15
Statistically significant results for efficacy of the experimental intervention 16 Use of a predefined method for collecting data on harm (eg, a questionnaire focusing on adverse events, specific items listed on the case report form) 17 Predefinition of severity of harm (ie, by using grades of severity of adverse events or listing adverse events that were considered as serious or severe) *Absence of funding was considered public funding if the study was performed by academics, hospital practitioners, or health authorities. y An intervention was considered to be innovative if it was not yet marketed or tested or if it had a complex and innovative mechanism of action.
